Tenecteplase for acute non–large vessel occlusion 4.5 to 24 hours after ischemic stroke
About The Study: Among patients with non–large vessel occlusion acute ischemic stroke and salvageable brain tissue, intravenous tenecteplase, a modified human tissue plasminogen activator, administered 4.5 to 24 hours after onset resulted in a greater likelihood of an excellent functional outcome at 90 days than standard care but had an increased risk of symptomatic intracranial hemorrhage.
Corresponding Author: To contact the corresponding author, Junwei Hao, MD, PhD, email haojunwei@vip.163.com.
To ...